Nektar Therapeutics stock
NKTRNASDAQHealthcareISIN US6402683063
29Score 29 out of 100, Weak
Price and trend
41 / 100
Price history
−35% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 43% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 50).
The price is 63% below its 52-week high. Largest decline in 20 years: 100% (March 2018 to November 2023).
Chart figures for advanced users
- SMA 50$49.26
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$65.04
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)50
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$35.12
- The lowest closing price of the last twelve months.
- Resistance$100.35
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Nektar Therapeutics belongs to the Biotechnology industry (United States) and, with a market value of $1.27B, is number 171 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $55.23M (down 43.9% year on year) and a loss of $164.08M.
- MEQIRI Score 29 out of 100 (Weak): rank 685 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $684.34M, financial debt $135.93M.Stability 53
Weaknesses
- DilutionShare count up 42% since 2020.Capital allocation 18
- Revenue shrinkingRevenue down 18.4% a year since 2020.Growth 32
- Loss-makingLoss of $177.26M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 16.6% on the twelve months before. Revenue has declined since 2006 (-7% per year), so it is worth watching closely.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −237%, net −297%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Mar 2027in 109 days
- Last reported
- 12 Nov 2026EPS reported −$1.63 (expected −$2.07)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$8.080.0%
- Revenue
- $41.82M0.0%
- Earnings per share
- −$10.500.0%
- Revenue
- $53.42M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −4.0%Guidance for year-end 2026 cash and investments raised to about $815 million to $840 million.
“We are increasing our cash guidance for year end 2026 and we now expect to end 2026 with approximately $815 million to $840 million in cash and investments.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $2.03M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Zalevsky JonathanSale
18 Aug 2026, Chief R&D Officer
- Shares
- 186
- Price
- $71.98
- Value
- $13,388
- Robin Howard WSale
18 Aug 2026, President & CEO
- Shares
- 418
- Price
- $71.98
- Value
- $30,088
- Zalevsky JonathanSale
30 Jun 2026, Chief R&D Officer
- Shares
- 5,681
- Price
- $70.00
- Value
- $397,670
Show 5 more
- Robin Howard WSale
17 Jun 2026, President & CEO
- Shares
- 10,000
- Price
- $61.19
- Value
- $611,880
- Robin Howard WSale
16 Jun 2026, President & CEO
- Shares
- 10,000
- Price
- $60.32
- Value
- $603,176
- Zalevsky JonathanSale
15 Jun 2026, Chief R&D Officer
- Shares
- 5,538
- Price
- $60.71
- Value
- $336,212
- Zalevsky JonathanSale
19 May 2026, Chief R&D Officer
- Shares
- 199
- Price
- $65.51
- Value
- $13,036
- Robin Howard WSale
19 May 2026, President & CEO
- Shares
- 444
- Price
- $65.51
- Value
- $29,086
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Nektar Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 29
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- UroGen PharmaURGN $1.29B36
- Inhibrx BiosciencesINBX $1.29B33
- COMPASS PathwaysCMPS $1.28B35
- IdorsiaIDIA.SW $1.28B35
- GH ResearchGHRS $1.27B36
- KardiganKARD $1.26B44
- Rapport TherapeuticsRAPP $1.24B33
- Alpha Tau MedicalDRTS $1.24B42
ETFs that hold Nektar Therapeutics
Held by 8 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.5B |
Show 4 more
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.02% | 0.30% | €944.34M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.